About Tubulin beta-2A chain
Tubulin beta-2A chain (TUBB2A) is a protein
from Homo sapiens identified by UniProt accession
Q13885, 445 residues long.
MolForge cross-references it against 0 known binders and
553 disease associations.
Target properties
| Protein name | Tubulin beta-2A chain |
| UniProt accession | Q13885 |
| Gene | TUBB2A |
| Organism | Homo sapiens |
| Length | 445 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (553)
Diseases linked to this target (Open Targets).
- complex cortical dysplasia with other brain malformations 5 · score 0.73
- Genetic central nervous system malformation · score 0.71
- breast cancer · score 0.62
- non-small cell lung carcinoma · score 0.61
- neoplasm · score 0.60
- breast carcinoma · score 0.60
- breast neoplasm · score 0.60
- gout · score 0.59
- acute lymphoblastic leukemia · score 0.59
- Hodgkins lymphoma · score 0.59
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q13885-F1 | alphafold | PREDICTED | 92.33 | — |
Amino-acid sequence (445 residues)
MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPTGSYHGDS DLQLERINVY YNEAAGNKYV PRAILVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN WAKGHYTEGA ELVDSVLDVV RKESESCDCL QGFQLTHSLG GGTGSGMGTL LISKIREEYP DRIMNTFSVM PSPKVSDTVV EPYNATLSVH QLVENTDETY SIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL RKLAVNMVPF PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQMFDSKNMM AACDPRHGRY LTVAAIFRGR MSMKEVDEQM LNVQNKNSSY FVEWIPNNVK TAVCDIPPRG LKMSATFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG EGMDEMEFTE AESNMNDLVS EYQQYQDATA DEQGEFEEEE GEDEA
Explore Tubulin beta-2A chain with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets